Home
October 2009 November 2009 December 2009
Su Mo Tu We Th Fr Sa
Week 45 1 2 3 4 5 6 7
Week 46 8 9 10 11 12 13 14
Week 47 15 16 17 18 19 20 21
Week 48 22 23 24 25 26 27 28
Week 49 29 30
Reach urologists

The Value of Combined Use of Survivin, Cytokeratin 20 and Mucin 7 mRNA for Bladder Cancer Detection in Voided Urine - Abstract Show Comments PDF Print E-mail
  
Wednesday, 09 January 2008

Department of Urology, Guangdong Provincial People’s Hospital, Number 106, the 2nd Road of Zhongshan, Guangzhou, Guangdong, 510080, China

This email address is being protected from spam bots, you need Javascript enabled to view it

To evaluate the value of combined use of survivin, cytokeratin (CK) 20 and mucin (MUC) 7 mRNA in comparison with voided urine cytology in the detection of bladder cancer patients.

One hundred and fifty three patients and 20 healthy volunteers were evaluated by RT-PCR for detecting survivin, CK-20 and MUC7 mRNA in voided urine before cystoscopy. The three markers and cytology were evaluated independently or in combinations.

The overall sensitivity and specificity were 90.4 and 94.7% for survivin, 82.6 and 97.4% for CK-20, 62.6 and 94.7% for MUC7 and 46.0 and 100% for voided urine cytology. Combined sensitivity of voided urine cytology with the three biomarkers together was higher than either combined sensitivity of voided urine cytology with one of the biomarkers or than that of the biomarker alone.

Combined use of the three markers can improve the sensitivity for detecting bladder cancer.

Written by
Pu XY, Wang ZP, Chen YR, Wang XH, Wu YL, Wang HP.

Reference
J Cancer Res Clin Oncol. 2007 Nov 20 [Epub ahead of print]
doi:10.1007/s00432-007-0331-9

PubMed Abstract
PMID:18026991

UroToday.com Bladder Cancer Section

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 0
PoorBest


 

Bookmark and Share
< Prev   Next >

Member's Section

Login

Sign Up

Quick Search

Meet the Expert


All Experts


Featured Conference

Media and Publisher

Advertising Rates
Reprints

Working with Industry

Case Studies
Sponsorship Opportunities

Bladder Cancer
Sponsored By